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Abstract: There has been an increase in the concern about preventing type 2 diabetes mellitus 
(T2DM), a disease with great and increasing prevalence. The prevalence of obesity, physical 
inactivity, Western processed diet, important risk factors for the development of T2DM, are also 
rising. Free fatty acids are increased in obesity and reduce insulin clearance and increase hepatic 
glucose production. Implementation of a healthy lifestyle has been show to slow the progression 
of impaired glucose tolerance to T2DM. Orlistat is an inhibitor of lipase activity, with proved 
efﬁ  cacy in body weight reduction and long-term management of obesity and more favorable 
effects on carbohydrate metabolism and it was prospectively shown in XENDOS study that orlistat 
promoted long-term weight loss and prevented T2DM onset in obese individuals with normal 
and impaired glucose tolerance at baseline over four years. This beneﬁ  t could be associated to 
the weight loss itself, to the limited absorption of lipids and reduction of plasma free fatty acids, 
to increased production of incretins or to modulation of secretion of cytokines by adipocytes, all 
effects secondary to orlistat treatment. A proposed strategy is to identify subjects at highest risk 
to receive a drug intervention, using lifestyle interventions alone at the community level.
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Prevalence
There has been an increase in the concern about preventing the most usual type of 
diabetes, type 2 diabetes mellitus (T2DM). The public health burden of T2DM has 
been powerfully increased throughout the world, because T2DM remains a progres-
sive disease. T2DM affects about 5% of Western populations and an estimated 170 
million individuals worldwide (Wild et al 2004). In the US, the prevalence of T2DM 
increased 33% from 1990 to 1998 (Mokdad et al 2000), was accountable for an esti-
mated US$132 billion in direct and indirect costs in 2002 and T2DM is the ﬁ  fth leading 
cause of death (ADA 2003). Moreover, the lifetime risk for developing T2DM was 
estimated to be 32.8% and 38.5%, respectively, for a man and a woman born in 2000 
in the US (Narayan et al 2003). Not only the relatively great prevalence at present, but 
also the alarming increase in T2DM incidence in the coming decades, possibly caused 
by changes in human environment, lifestyle, and genetic susceptibility, can give rise 
to a global health problem. The number of diabetic individuals – the majority of them 
with T2DM – is projected to double, reaching about 350 million by the year 2025 (IDF 
2006) and 360 million by 2030 (Wild et al 2004). By the reason of the escalating rate of 
T2DM and metabolic syndrome, is expected a concomitant increase in cardiovascular 
morbidity and mortality, coronary artery disease, end-stage renal disease, blindness, 
and lower extremity amputations (Isomaa et al 2001; Prisant 2004).
Obesity and type 2 diabetes
The pathogenesis of T2DM within the perception of the metabolic syndrome has been 
considered by Reaven in his Banting lecture (1988). He postulated that insulin resistance Vascular Health and Risk Management 2008:4(2) 326
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and consequent hyperinsulinemia could be the mutual 
pathological antecedents of the cardiovascular atherosclerotic 
pathological conditions (Reaven 1988). It is well known that 
the risk of developing clinical T2DM is strongly enhanced in 
the state of impaired glucose regulation or pre-diabetic states 
(impaired fasting glycemia or impaired glucose tolerance) 
and also the risk of developing cardiovascular complications 
is increased in these early states of glucose intolerance 
(Uwin et al 2002). In the impaired glucose tolerance state, 
postprandial blood glucose levels are moderately elevated, 
while on the contrary, fasting blood glucose can generally be 
maintained within the normal or near-normal range.
All-cause mortality associated with the pre-diabetic states 
is almost 2 times higher compared with normal glucose 
tolerance, and mortality per 1000 person-years is 20.8% 
and 40.9%, respectively, for impaired glucose tolerance 
and for T2DM (Saydah et al 2001). Despite the fact that 
impaired glucose tolerance is frequently unrecognized, 17% 
of overweight Americans may have this state (Benjamin 
et al 2003). According to an expert guideline, the American 
Diabetes Association advises physicians taking into account 
screening for T2DM subjects with risk factors such as family 
history, overweight, gestational diabetes and hypertension 
(ECDCDM 1997). Menopause (Wu et al 2001) and hyper-
lipidemia (ADA Clinical Practice Recommendations 2004) 
are factors that also increase the risk of T2DM.
Comparably, the prevalence of obesity is also rising, with 
more than 60% of Americans, more than 50% of Europeans 
and Australians, and more than 40% of Brazilians con-
temporarily classiﬁ  ed as overweight (Monteiro et al 2000; 
WHO 2000; James et al 2004). Between 1992 and 2002, 
the prevalence of overweight and obesity increased in all 
gender and age groups in China. The combined prevalence 
of overweight and obesity increased from 14.6% to 21.8% 
(Wang et al 2007). The increase in prevalence in China over 
the last 20 years was 400% (APCSC 2007). Obesity is the 
most important single risk factor for T2DM. Epidemiologic 
studies suggest that obesity and inactivity are substantial 
predictors for the development of T2DM among women 
(Hu et al 1999, 2001).
The Nurses’ Health Study established that a body mass 
index (BMI) in the upper normal range was correlated with 
an increased risk of T2DM. Women with a BMI of 35 
kg/m2 or more had almost a 40-fold risk to develop T2DM 
compared with women with BMI lower than 23 kg/m2. This 
study also documented that weight change has a powerful 
inﬂ  uence on the risk of T2DM. A weight gain between 11 and 
19.9 kg after 18 years of age represented a more than 5-fold 
risk of developing T2DM (Colditz et al 1995). Comparable 
information was documented for men in the Health Profes-
sionals’ Study. In this study, data from a cohort of 51,529 US 
adult male health professionals were analyzed and individuals 
with a body mass index (BMI) of 35 kg/m2 or more had a 
42-fold relative risk to become T2DM compared with men 
with BMI lower than 23 kg/m2. Moreover, waist circumfer-
ence in the highest quintile was directly correlated to T2DM 
risk (Chan et al 1994).
Indeed, obesity and particularly intraabdominal adipos-
ity with visceral fat deposition, is one modiﬁ  able risk factor 
directly involved in the increased prevalence of T2DM 
(Tuomilehto et al 2001). Visceral adipocytes have a higher 
metabolic turnover rate than peripheral adipocytes and the 
free fatty acids (FFA) are released in high concentrations 
and drained straight to the liver via the portal vein. Free fatty 
acids reduce insulin clearance and increase hepatic glucose 
production. Diminishing body fat has been show to slow the 
progression of impaired glucose tolerance to T2DM (Hu et al 
2001). The risk of T2DM development in individuals with 
the central pattern of fat distribution is higher than the risk 
in individuals with a gluteal-femoral or peripheral type of 
fat distribution (Kissebah and Krakower 1994). A study of 
Japanese Americans evidenced that CT-mensurated intra-
abdominal fat area persisted a signiﬁ  cant predictor of T2DM 
incidence still after adjustment for BMI, total body fat area 
and other risk factors for T2DM (Boyko et al 2000).
Visceral fat is the source of a number of substances which 
might play a role in the development of a cronic inﬂ  amma-
tory (Dandona et al 2004) and insulin-resistant state (Calles-
Escandon and Cipolla 2001), as well as inadequate survival 
of pancreatic beta cells (Eldor and Raz 2006). These are 
interrelated metabolic abnormalities that are the root in the 
etiology of T2DM. Among these are tumor necrosis factor-
alpha (TNF-α), interleukin 6 (IL-6), resistin, visfatin, and 
adiponectin (Borst 2004). The levels of these adipocytokines 
can be modulated by weight loss, with associated changes 
in insulin sensibility (Corpeleijn et al 2005). Hypoadiponec-
tinemia may contribute to several aspects of the metabolic 
phenotype of speciﬁ  c ethnic groups, particularly, an increased 
central obesity and visceral fat and a remarkable increased 
risk of T2DM (Retnakaran et al 2006). Therefore, therapeutic 
strategies reducing pro-inﬂ  ammatory cytokines and/or raising 
anti-inﬂ  ammatory adiponectin may have a favorable effect 
in selected individuals.
Moreover, there is now evidence that impaired adipogen-
esis, adipocyte hypertrophy and pro-inﬂ  ammatory factors 
may have an important role in the pathogenesis of T2DM. In Vascular Health and Risk Management 2008:4(2) 327
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fact, during positive energy balance, energy is stored as body 
fat, which serves important purposes, such as the release of 
fatty acids during fasting states, thus allowing fat oxidation 
by skeletal muscle. The storage of fat (lipogenesis) is ﬁ  rst 
accomplished through enlargement of fat cells (hypertrophy). 
Further storage requires the recruitment, proliferation and 
differentiation of adypocites (adipogenesis). If adipogenesis 
is impaired, progressive adipocyte hypertrophy would lead 
to metabolic diseases related to excessive fat accumulation, 
among them T2DM (Bays 2005; Bays et al 2006).
Physical activity and type 2 diabetes
In addition to adiposity, physical activity is also a modiﬁ  able 
risk factor for T2DM. Individuals who are dynamical and 
active have a low prevalence of T2DM. However, if they 
they make a rapid shift from traditional rural active lifestyle 
to a modern western urbanized sedentary lifestyle, incidence 
of T2DM boosts (Knowler et al 1990). This phenomenon 
could be seen in Pima Indians (Knowler et al 1990), in the 
South Asian population in the UK (Mather and Keen 1985), 
but also in Japanese immigrants in the Southwest of Brazil 
(Ferreira et al 2002). Physical activity straightly enhances 
insulin-dependent glucose removal by the skeletal muscle, 
reduces visceral fat mass, and consequently improves insulin 
resistance (Kriska et al 2001). In fact, a more recent analysis 
of the Nurses’ Health Study, including 84,941 female nurses 
followed for 16 years, showed that women with a health 
lifestyle had a much lower risk of developing T2DM than the 
general population. Women who exercised at least 7 hours 
per week reduced the risk of T2DM by 39% compared with 
women who exercised less than half hour per week (Hu et al 
2001). In 7735 British men who were 40 to 59 years of age, 
moderate physical activity substantially diminished the risk 
of T2DM relative to sedentary men, after adjustment for BMI 
and age (Perry et al 1995).
An interesting recent health examination compared the 
age- and gender-adjusted prevalence of T2DM, obesity 
and lifestyle in two populations of Pima Indians that share 
considerable genetic similarity, but do not share the same 
environment: one living in the traditional environment in 
the Sierra Madre Mountains of Mexico and the other living 
in a western environment in Arizona, USA. The prevalence 
of T2DM in the Mexican Pima Indians was 6.9%, less than 
one-ﬁ  fth that in the US Pima Indians (38%) and similar to 
that of non-Pima Mexicans (2.6%). The prevalence of obesity 
was comparable in the Mexican Pima Indians (7% in men 
and 20% in women) and non-Pima Mexicans (respectively 
9% and 27%), but much lower than in the US Pima Indians 
(respectively 64% and 75%). Levels of physical activity 
were much higher in both Mexican groups than in US Pima 
Indians (Schulz et al 2006).
Dietary factors and type 2 diabetes
Dietary factors certainly play a role as another modiﬁ  able 
risk factor for T2DM. In the Health Professionals study, a 
diet high in whole grains was associated with a lower risk 
of T2DM (Fung et al 2002). The consumption of a diet rich 
in vegetables, fruit, ﬁ  sh, poultry and whole grains leads to 
a diminished risk of developing T2DM, when compared to 
a high consumption of a typical western diet based in red 
and processed meat (Fung et al 2004), dairy and high-fat 
ingredients (Meyer et al 2000; Van Dam et al 2002). A large 
cross-sectional study documented that a 40 g enhancement 
in daily fat intake yielded an increased risk of impaired 
glucose tolerance and T2DM, but it is not clearly evident if 
this increased risk is conditioned to the obese state or to the 
fat ingestion (Marshall et al 1991). The identiﬁ  cation of risk 
factors is basic for the favorable implementation of preven-
tion programs (Table 1).
Lifestyle modiﬁ  cation is likely to have important effects 
on the morbidity and mortality of diabetes and should be 
recommended to all high-risk people. Recent results from 
the Finnish Diabetes Prevention Study showed that lifestyle 
interventions to prevent T2DM in men and women with 
impaired glucose tolerance are cost-effective (Lindgren et al 
2007), although the program used in the DPP study was too 
expensive for a national program to be implemented (Eddy 
et al 2005).
T2DM is, therefore, a heterogeneous and polygenic 
disorder. Although our understanding of the etiology and 
pathogenesis of this disease is not complete, it is known that 
T2DM is the result of both insulin resistance and relative 
insulin deﬁ  ciency (Edelstein et al 1997; Weyer et al 1999). 
Insulin resistance is a fundamental defect known to precede 
the onset of T2DM by many years. In some subjects, beta-
cells counterbalance for insulin resistance by enhanced 
insulin secretion and T2DM does not develop. Nevertheless, 
in many pre-diabetic individuals, beta-cell compensation to 
insulin resistance is ineffectively performed, and a hyper-
glycemic condition is generated.
Nonpharmacological modes 
of  T2DM prevention
A huge number of studies address several forms by which 
T2DM could be prevented. Lifestyle changes, food intake 
modifications – for instance, lowering the fat content Vascular Health and Risk Management 2008:4(2) 328
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(Lovejoy 1999; Van Dam et al 2002) or enhancing the ﬁ  ber 
and magnesium content of the diet (Lopez-Ridaura et al 
2004) – and/or physical activity promoting weight loss 
(Eriksson and Lindgarde 1991; Pan et al 1997; Swinburn et al 
2001; Tuomilehto et al 2001; Knowler et al 2002; Kosaka et al 
2005), smoking status (Tuomilehto 2005), moderate coffee 
(Van Dam and Hu 2005) and moderate alcohol consumption 
(Conigrave et al 2001), and ﬁ  nally bariatric gastric surgery 
(Sjöström et al 2004) may be of beneﬁ  t in the prevention of 
T2DM in morbidly obese patients (Gruber et al 2006).
These data lend powerful credence to the signiﬁ  cant 
weight of lifestyle changes in T2DM prevention, but regard-
less of the fact that these modiﬁ  cations look to be operative in 
the prevention, it is highly questionable if these interventions 
would be sustained for the long-term. By the other hand, it is 
very clear that health providers need to assist their overweight 
patients with weight control (Tsai and Wadden 2005).
Pharmacological modes 
of   T2DM prevention: antidiabetic, 
antihypertensive, hypolipidemic 
agents; hormone replacement 
therapy
In addition to lifestyle modiﬁ  cations and education, many 
oral antidiabetic agents have been evaluated in the context 
of T2DM prevention, showing reduction of incident T2DM. 
Although these post hoc analysis arouse interest and provoca-
tive reaction, these agents are glucose-lowering drugs, so 
that the clinical beneﬁ  ts in undoubtedly preventing T2DM 
has yet to be proved. Among there antidiabetic agents are: 
metformin in the US DPP Study (Knowler et al 2002), and 
possibly in the mid-term 3-year analysis of the ongoing 
EDIT trial (Scheen 2003); troglitazone in the TRIPOD 
interventional study in Hispanic women with a history of 
gestational diabetes (Buchanan et al 2002); acarbose in the 
STOP-NIDDM trial (Chiasson et al 2003), and also likely 
in mid-analysis of the EDIT trial (Scheen 2003), and rosi-
glitazone in the recently published DREAM trial (DREAM 
Trial Investigators 2006).
Also the role of blood pressure lowering agents has 
been studied in the prevention of T2DM in hypertensive 
patients. The rate of T2DM development was lower among 
ramipril-treated subjects in the HOPE trial (HOPE Study 
Investigators 2000), among captopril-treated patients in 
CAPP study (Hansson et al 1999) and among lisinopril-
treated individuals in ALLHAT trial (ALLHAT 2002), 
expressing the well-known insulin sensitizing effect of 
angiotensin-converting-enzyme inhibitors, but also showing 
unfavorable effects of the conventional therapy (diuretics 
or beta-blockers). Compared to atenolol, losartan reduced 
the new incident cases of T2DM in the LIFE study (Dahlof 
et al 2002), but a possible limitation is that atenolol seems 
to promote T2DM, and hence, it is not possible to evaluate 
how protective losartan was. In the VALUE trial, valsartan 
reduced the risk of T2DM, when compared to amlodipine 
(Julius et al 2004). Treatment with candesartan decreased 
T2DM incidence in the ALPINE study in newly detected 
hypertensives (Lindholm et al 2003) and also in the CHARM 
trial in patients with heart failure (Yusuf et al 2005). 
Compared to diuretics, the rate of T2DM occurrence was 
lower among nifedipine-treated patients in INSIGHT study 
(Mancia et al 2003) and with amlodipine-treated individuals 
in the ALLHAT trial (ALLHAT 2002), may be reﬂ  ecting 
adverse effects of diuretics or beta-blockers rather than 
beneﬁ  cial effects of calcium channel blockers. Similarly, 
amlodipine (adding perindopril as required) in the ASCOT 
trial induced less T2DM than the combination atenolol and 
bendroﬂ  umethiazide (Dahlof et al 2005), and in the INVEST 
study a verapamil plus trandolapril-based regimen reduced 
the risk of new T2DM compared with a treatment based on 
hydrochlorothiazide plus atenolol (Pepine et al 2003).
The role of hypolipidemic agents in T2DM prevention 
was assessed. In the WOSCOPS study with pravastatin, a 
reduction of incident T2DM was observed (Freeman et al 
2001) and the same was observed in the BIP study with 
bezaﬁ  brate retard (Tenenbaum et al 2004).
The answer to the query whether hormone replacement 
therapy is a feasible way to T2DM prevention persists 
uncertain. Although the risk of T2DM increased with the 
duration of estrogen use in Strong Heart study with post-
menopausal American Indian women (Zhang et al 2002), a 
reduction in incident T2DM was detected with a combination 
Table 1 Modiﬁ  able and nonmodiﬁ  able risk factors for imple-
mentation of T2DM prevention programs
Modiﬁ  able factors  Non-modiﬁ  able factors
Obesity (mainly abdominal adiposity)  Ethnicity
Physical inactivity  Age
Smoking Gender
Low ﬁ  ber content of the diet  Genetic factors
High saturated fat/high trans fat in   Prior glucose intolerance/ 
the diet/high processed meat intake  gestational diabetes
Low magnesium intake  Low birth weight
Low coffee/alcohol intake  Hypertension
Psychosocial stress  High triglyceride/Low HDL 
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of conjugated estrogen and medroxyprogesterone acetate in 
the HERS study with women with coronary heart disease 
(Kanaya et al 2003).
Pharmacological modes of   T2DM 
prevention: antiobesity agents
As formerly affirmed, a modest 10% weight reduction 
(Eriksson and Lindgarde 1991; Pan et al 1997; Swinburn et al 
2001; Tuomilehto et al 2001; Knowler et al 2002; Kosaka 
et al 2005) and larger weight reduction through gastric 
surgery (Sjöström et al 2004; Pontiroli et al 2005) predict a 
reduced risk of T2DM. So, effective obesity therapies could 
improve glycemic status and prevent new T2DM (Padwal 
and Laupacis 2004; Padwal et al 2005).
It is reasonable to conclude that weight reduction with 
effective antiobesity agents (Halpern and Mancini 2005) may 
contribute to delay or prevent the progression from impaired 
glucose tolerance to overt T2DM in at risk obese individuals, 
but this datum is not available with most drugs used to treat 
obesity. A large long-term prospective study is ongoing with 
over 9000 patients (the Sibutramine Cardiovascular and dia-
betes OUTcome study) to examine wether or not sibutramine 
reduces the risk for cardiovascular complications in subjects 
at high risk for heart disease and should better determine the 
place of sibutramine in the prevention of T2DM (although 
T2DM is not a predeﬁ  ned endpoint of the study) (James 
2005). Another ongoing randomized double-blind placebo-
controlled trial (CRESCENDO) of rimonabant for reducing 
the risk of major cardiovascular events in abdominally 
obese patients with clustering risk factors may determine 
if treatment with rimonabant can prevent T2DM (though it 
is not a predeﬁ  ned endpoint) (see http://www.clinicaltrials.
gov/ct/show/NCT00263042?order=2).
Orlistat is a speciﬁ  c and strong oral inhibitor of gastroin-
testinal lipase activity, achieving a 47% to 91% gastric lipase 
inhibition and a 51% to 82% pancreatic lipase inhibition 
in healthy volunteers (Carriere et al 2001). These lipases 
are responsible for the hydrolysis of ingested triglycerides 
into fatty acids and monoglycerides, which are therefore 
absorbed by the enterocytes. Orlistat has insigniﬁ  cant or no 
activity against phospholipases, chymotrypsin, trypsin and 
amylase. By orlistat action, ingested fat absorption is reduced 
by approximately one third and the nonabsorbed unbroken 
triglycerides, as well as orlistat, are eliminated in the feces 
(Guerciolini 1997). Orlistat has no systemic action, due to 
its minimal limited absorption (Zhi et al 1995).
The efﬁ  cacy of orlistat in body weight reduction and 
long-term management of obesity has been shown in two 
large multicentre randomized double-blind 2-year trials, with 
1187 (Sjöström et al 1998) and 743 obese patients (Davidson 
et al 1999). At the end of this study, patients receiving orlistat 
had lower plasma insulin levels compared to the levels at the 
beginning of the trial while these levels were not signiﬁ  cantly 
different in placebo-treated patients (64.5 vs 84.0 pmol/L 
and 86.4 vs 86.3 pmol/L, respectively, p = 0.04 between 
treatment groups). In the same study, the orlistat group had 
a lower increase in fasting serum glucose levels than the 
placebo group (+0.06 mmol/L vs +0.26 mmol/L, respectively, 
p = 0.001 between treatment groups). Furthermore, at the 
end of the multicentre European study (Sjöström et al 1998), 
orlistat also generated greater improvements in serum insulin 
and glucose levels after 1 and 2 years, when compared to 
the placebo group.
One European study assessed the impact of orlistat on 
weight loss, glycemic control and serum lipid levels in 391 
obese patients with T2DM on sulphonylurea medications 
for one year and concluded that it is an effective treatment 
(Hollander et al 1998). Comparable results were achieved by 
Kelley and colleagues (2002) in obese diabetic patients on 
insulin and by Miles and colleagues (2002) in obese diabetic 
patients on sulphonylurea or metformin. Miles and colleagues 
(2002) also reported that 1-year treatment with orlistat was 
associated with signiﬁ  cant improvement in blood pressure in 
orlistat-treated subjects, as well as greater improvements in 
total cholesterol and LDL cholesterol compared with placebo 
in overweight and obese patients with T2DM treated with 
metformin, consistent with the reduction in LDL/HDL ratio 
documented in many studies (Sjöström et al 1998; Rossner 
et al 2000; Kelley et al 2002; Halpern et al 2003). In these 
studies, all participants were encouraged to adhere to a low 
fat, weight reduction diet. One Latin-American trial of orlistat 
evaluating improvement in glycemic proﬁ  le in obese diabetic 
patients demonstrated that subjects treated with orlistat plus a 
mildly controlled energy diet counseling for six months lost 
signiﬁ  cantly more weight than those treated with placebo plus 
diet, and that, in addition, orlistat treatment was associated 
with greater improvements in diabetic metabolic parameters, 
lipid proﬁ  le and anthropometric risk factors (Halpern et al 
2003). Another 6-month study in a cohort of severely young 
obese diabetic Chinese patients reduced the levels of glyco-
sylated hemoglobin and fasting plasma glucose (Tong et al 
2002). In general, these studies showed that more patients 
in the orlistat group than in placebo group either reduced or 
discontinued one or more antidiabetic drugs or reduced insu-
lin dose and, in opposition, more placebo-treated patients, 
compared with orlistat-treated subjects required supplemental Vascular Health and Risk Management 2008:4(2) 330
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dosages of antidiabetic medications. The improvements in 
glycemic proﬁ  le accomplished in orlistat-treated diabetic 
individuals in some studies (Halpern et al 2003; Didangelos 
et al 2004) can be comparable to those documented in trials 
with antidiabetic medications (Hoffmann and Spengler 1994, 
1997; Johansen 1999).
These observations suggest that orlistat may be an 
efﬁ  cient and a safe adjunct to dietary intervention and con-
ventional antidiabetic pharmacotherapy in the global treat-
ment of obese diabetic patients and several meta-analyses 
have concluded that orlistat is effective in the treatment of 
T2DM in obese patients (Keating and Jarvis 2001; Scheen 
and Ernest 2002).
An initial effort to state that anti-obesity drugs could pre-
vent T2DM was a multicenter evaluation of orlistat, a pooled 
post hoc analysis (n = 675 obese adults with impaired glucose 
tolerance treated for a men follow-up of 582 days) of three 
randomized, placebo-controlled clinical trials (Heymsﬁ  eld 
et al 2000). Obese nondiabetic individuals received either 
orlistat (120 mg three times a day with food) or placebo 
for two years, combined with a mild low energy diet. In 
orlistat group, less subjects with impaired glucose tolerance 
at baseline developed T2DM (3%) compared to subjects 
in placebo group (7.6%). Moreover, considering individu-
als with impaired glucose tolerance, fasting glucose levels 
normalized in more orlistat-treated patients than in placebo-
treated subjects (respectively, 72% vs 49%, p = 0.04). These 
ﬁ  ndings denote that orlistat treatment has a more favorable 
effect than placebo on carbohydrate metabolism and can 
prevent T2DM onset in obese individuals with impaired 
glucose tolerance at baseline. This report was a retrospective 
meta-analysis and conﬁ  rmation of the results by prospective 
trials was needed.
This ratiﬁ  cation came from the XENDOS study (Torger-
son et al 2004), a prospective multicenter randomized double-
blind, placebo-controlled, parallel group study, performed 
in Sweden over a period of four years, aimed to investigate 
the effectiveness of orlistat plus lifestyle changes compared 
with lifestyle modiﬁ  cations alone in 3 305 patients with BMI 
30 kg/m2, for T2DM prevention. This is one important 
difference between XENDOS study and other prevention 
studies: both groups in XENDOS were prescribed intensive 
lifestyle modiﬁ  cations, besides receiving either a placebo 
or an active treatment. Non-diabetic subjects were enrolled, 
21% with impaired glucose tolerance, 79% with normal 
glucose tolerance and randomized to orlistat (120 mg three 
times a day with meals) or matched placebo. The average 
compliance with the study drug from ﬁ  rst dose until treatment 
termination was 93% for orlistat patients and placebo 
patients. Overall, 4% of placebo patients and 8% of orlistat 
patients withdrew from the study because of adverse events 
or laboratory abnormalities (mainly due to gastrointestinal 
events). A diet was prescribed with an intense daily calorie 
deﬁ  cit of 800 kcal from the estimated total daily energy 
expenditure. In addition, all individuals were encouraged to 
participate in moderate daily physical exercise. A 75 g oral 
glucose tolerance test was performed at baseline and every 
six months (Torgerson et al 2004).
Weight loss was greater in orlistat group (–6.9 kg, n = 1640 
completers; –5.8 kg in LOCF analysis) than in placebo group 
(–4.1 kg, n = 1647 completers; –3 kg in LOCF analysis, 
p = 0.001). Regional body composition study with comput-
erized tomography at the fourth lumbar vertebra showed 
signiﬁ  cant visceral adipose tissue reduction in orlistat-treated 
patients, but not in placebo-treated patients (Brandberg et al 
2003). It is remarkable that the placebo group was treated 
with lifestyle modiﬁ  cations and lost an expressive amount 
of weight throughout the study, comparable with that in 
intensive lifestyle intervention branches of other preventive 
studies (Tuohmilehto et al 2001; Knowler et al 2002). In spite 
of that, the difference in weight loss between groups was 
able to diminish T2DM incidence (6.2% in orlistat-treated 
patients vs 9.0% in placebo-treated subjects, p = 0.003, RR 
reduction = 37.3%). Moreover, the weight loss achieved by 
patients with impaired glucose tolerance with orlistat plus 
lifestyle intervention was comparable to that of normal glu-
cose tolerance subjects (Torgerson et al 2004).
In obese individuals with impaired glucose tolerance, 
the conversion rate to T2DM was 28.8% in placebo-treated 
patients vs 18.8% in orlistat-treated patients (p = 0.002, RR 
reduction = 45%) (Figure 1). Since the accumulative inci-
dence of T2DM in subjects with normal glucose tolerance 
at baseline was low, no difference was perceptible between 
orlistat-treated and placebo-treated individuals in this sub-
group. In spite of this, there was a signiﬁ  cant reduction in 
fasting insulin levels at the end of ﬁ  rst and fourth year in 
the orlistat-treated population (p  0.001 between treatment 
groups) (Torgerson et al 2004). The accumulative occurrence 
of T2DM in placebo-treated patients with impaired glucose 
tolerance (14.2%) was comparable to that of the intensive 
lifestyle intervention arms of other preventive studies (11% 
and 14.4%) (Tuohmilehto et al 2001; Knowler et al 2002), but 
the inclusion of orlistat to lifestyle changes reduced incident 
T2DM in individuals with impaired glucose tolerance by 
more than 50% when compared with placebo-treated patients 
(Torgerson et al 2004). The number of obese patients with Vascular Health and Risk Management 2008:4(2) 331
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impaired glucose tolerance needed to be treated (NNT) with 
orlistat plus lifestyle changes (rather than lifestyle changes 
alone) to avoid one case of T2DM was 10, but considering 
all participants, NNT was 36/4 years. XENDOS was the ﬁ  rst 
study to illustrate that the anti-obesity agent orlistat plus life-
style changes were able to improve weight loss and reduce 
incident T2DM in obese individuals above the result achieved 
with implementation of lifestyle modiﬁ  cations alone over 
four years. The preventive effect of orlistat in the studied 
subjects was mainly attributable to its favorable inﬂ  uence 
on individuals with impaired glucose tolerance.
Another recently published study evaluated efﬁ  cacy 
of orlistate in the maintenance of weight loss over 3 years 
following a major weight loss induced by very-low-energy 
diet (VLED) in abdominally obese patients with metabolic 
risk factors such as dyslipidemia, impaired fasting glucose 
and diet-treated T2DM. The addition of orlistate to lifestyle 
intervention was associated with maintenance of an extra 
2.4 kg weight loss after VLCD for up to 3 years and with a 
reduced occurrence of T2DM (Richelsen et al 2007).
Changes in inﬂ  ammatory mediators TNF-α and IL-6 
were evaluated before and after one year of treatment with 
orlistat and placebo in obese subjects. Weight reduction was 
associated with diminished levels of TNF-α and IL-6 in both 
groups, but at the end of the study, TNF-α and IL-6 levels 
were lower in orlistat-treated subjects (Samuelsson et al 
2003). A signiﬁ  cant reduction in leptin and high sensitive 
C-reactive protein, greater in orlistat-treated than in placebo-
treated patients was documented by Hsieh et al (2004) in a 
one-year study with 180 overweight individuals.
Another 6-month trial compared orlistat- and sibutramine-
treated morbidly obese women, and documented that, 
although orlistat group achieved a mean weight loss of 2.5% 
(nearly half of the weight loss of the sibutramine group) and 
did not show signiﬁ  cant change in metabolic parameters, 
surprisingly there was a greater and signiﬁ  cative decrease of 
resistin associated with comparable increase in adiponectin 
(Valsamakis et al 2004). A signiﬁ  cant increase in adiponectin 
in orlistat-treated patients was also observed by Hsieh and 
colleagues (2004).
It is known that a single dose of orlistat, given before 
a relatively high fat content meal in overweight patients 
with T2DM is associated with lower postprandial levels 
of plasma FFA compared with placebo (Tan et al 2002) 
and, since the publication of Randle’s original hypothesis 
(Randle et al 1963), many satisfactory and convincing stud-
ies have conﬁ  rmed that plasma levels of FFA can modulate 
the severity of insulin resistance in T2DM, inhibiting whole 
Figure 1 Incidence of T2DM by study group in XENDOS study. Cumulative incidence is shown in all obese patients and only in obese patients with impaired glucose toler-
ance at baseline. The decrease in the risk of developing diabetes with orlistat plus lifestyle intervention compared with placebo plus lifestyle intervention is indicated. P values 
shown are for the log-rank test. Copyright © 2004. Reproduced with permission from Torgerson JS, Hauptman J, Boldrin MN, et al. 2004. XENical in the prevention of diabetes 
in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 
27:155–61. Erratum in: Diabetes Care, 2004 27:856.Vascular Health and Risk Management 2008:4(2) 332
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body glucose utilization and oxidation (Ferrannini et al 1983; 
Piatti et al 1996; Randle 1998; Santomauro et al 1999; Kelley 
et al 2001).
A huge body of data documents that the clinical beneﬁ  t 
for the obese patient with T2DM usually depends on the 
extent of weight loss (Wing et al 1987, 1990; Williams et al 
1998). A very interesting 6-month trial examined weight 
loss-dependent and independent effects of orlistat, using 
behavioral intervention combined with placebo- controlled 
treatment with orlistat. Even though weight loss was nearly 
similar in orlistat and placebo-treated patients (nearly 
10% of baseline weight), and despite highly comparable 
changes in regional adiposity, including almost identical 
decrements of visceral adipose tissue, hepatic steatosis, 
and skeletal muscle fat content, improvement in insulin 
sensitivity measured by euglycemic hyperinsulinemic 
clamp was signiﬁ  cantly greater with orlistat therapy (Kelley 
et al 2004). This study showed that the improvement in 
insulin sensitivity was not related only to the negative 
energy balance and loss of adipose tissue, factors that did 
not account for the differential effect, because the rates and 
amounts of weight loss in both arms of the intervention 
were highly comparable. A differential treatment effect 
on plasma FFA likely contributed to the differences in the 
insulin sensibility status: there was greater reduction in 
fasting hyperinsulinemia and also in fasting and insulin-
suppressed plasma FFA in subjects receiving orlistat, 
probably related to effects on triglyceride absorption and 
postprandial lipemia, effect that persisted signiﬁ  cant even 
after statistical adjustment for weight loss. Plasma FFA 
levels were a strong correlate of insulin sensitivity both 
before and after weight loss.
Another possibility is an incretin response to orlistat treat-
ment. In fact, the reduced absorption of fat and the increase 
in intestinal fat content may lead to increased secretion of 
glucagon-like peptide 1 (GLP-1) and glucose-dependent 
insulinotropic peptide (GIP) (Thomsen et al 2003), gut 
hormones that are secreted in response to food intake, and 
stimulate insulin secretion (Vilsboll et al 2003). Orlistat 
increases postprandial GLP-1 levels, enhancing the insulin 
secretory response to the meal and blunting the postprandial 
rise in glucose in obese patients with T2DM. The increased 
GLP-1 levels, which lead to decreased food intake, may also 
contribute to the weight loss that is associated with the use 
of orlistat (Damci et al 2004).
Whether these ﬁ  ndings provide a physiopathological 
basis for the beneﬁ  ts in carbohydrate metabolism associated 
to the weight loss itself, to the limited absorption of lipids 
and reduction of plasma FFA, to increased production of 
incretins or to modulation of secretion of cytokines by fat 
cells (Table 2), all achieved by treatment with orlistat and 
lifestyle changes remains to be elucidated.
Genetic components – as well as behavioral and environ-
mental factors – modify the risk of occurrence of T2DM and 
some populations have a higher risk of developing T2DM. 
Consequently, experiments that involved a rather limited 
demographic sample may not be promptly generalized to 
the population as a whole. A proposed strategy is to identify 
subjects most likely to beneﬁ  t, or at highest risk to receive 
an aggressive and maybe multiple drug intervention, uni-
versalizing a planned effort at lifestyle interventions at the 
community level (Satterﬁ  eld et al 2003; Anderson Jr 2005; 
Norris et al 2006).
Specially with respect to oral hypoglycemic agents, but 
still in relation to orlistat, whether pharmacological pre-
ventive therapy merely postpone or mask the diagnosis of 
T2DM, instead of put forth an authentic preventive outcome 
is a critical and uncertain matter. Drugs that reduce plasma 
glucose levels may only reduce the concentrations to a limit 
situated below than that demanded for the precise diagnosis 
of T2DM. To show that T2DM is truly prevented, coming 
studies need to prove arrest of the pathological processes 
and since the interval between the beginning of beta-cell 
impaired function and development of T2DM according to 
the UK Prospective Diabetes Study (UKPDS) Group is about 
ten years (UKPDS Group 1995), surveillance periods will 
need to be considerably prolonged.
One can infer that probably long-term therapy with 
agents directed toward prevention of T2DM will be needed 
and that another important matter is the potential adverse 
events associated with pharmacological tactic for preven-
tion of T2DM. Gastrointestinal adverse events were partly 
responsible for discontinuation rates in XENDOS study 
(Torgerson et al 2004).
Table 2 Evidence for the beneﬁ  ts in carbohydrate metabolism 
and T2DM prevention achieved with orlistat treatment
Putative factor implicated in T2DM   Reference
prevention with orlistat
Reduction in free fatty acid levels  Tan et al 2002; Kelley  
  et al 2004
Reduction of proinﬂ  ammatory   Samuelsson et al 2003; 
adipocytokine levels  Valsamakis et al 2004
Enhancement in anti-inﬂ  ammatory  Valsamakis et al 2004
adipocytokine levels
Enhancement in incretin levels  Damci et al 2004Vascular Health and Risk Management 2008:4(2) 333
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A factor that must be considered in forming a decision 
about pharmacological T2DM preventive intervention is the 
cost-effectiveness of the therapy. Although supplementing 
standard T2DM management with orlistat seems to be a 
reasonably effective and cost-effective treatment option for 
overweight patients with T2DM (Maetzel et al 2003) and 
for the treatment of obesity if only treatment responders 
continue treatment (Foxcroft et al 2005; Lacey et al 2005), 
the cost-effectiveness of T2DM preventative intervention 
with orlistat was not yet documented.
Efforts should be directed to identify individuals with 
pre-diabetic states, family history of T2DM or high risk 
ethnic background and, from a public health point of view, 
preventive measures should ideally be focused in pediatric 
patients at high risk. In the future, genetic variations, as well 
as interactions between genetic and environmental pathways 
(Andrulionyte et al 2004; Zacharova et al 2005a, 2005b; 
Park et al 2006a, 2006b; Retnakaran et al 2006) may turn 
out T2DM prevention easier, affording the possibility of an 
individualized preventive measure based on this knowledge 
(Park 2004). New therapeutic agents with unique mode of 
action, incretins, stimulate the secretion of insulin, suppress 
glucagon secretion and increase the mass of pancreatic beta-
cells (Xu et al 1999; Meier et al 2003; Nauck and Meier 
2005). These agents, exenatide and liraglutide could halt and 
possibly prevent progression to T2DM, but further studies 
are certainly needed.
To summarize, an important body of evidence from large 
clinical trials establishes that T2DM is a preventable disease 
(ADA Clinical Practice Recommendations 2004). XENDOS 
study presented for the ﬁ  rst time that an antiobesity agent in 
combination with lifestyle interventions over four years is 
of greater beneﬁ  t than lifestyle attitude modiﬁ  cations alone, 
specially in high risk individuals with impaired glucose toler-
ance resulting in more weight loss and greater amelioration 
in cardiovascular risk factors.
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